Trials Group Of The Year: Quinn Emanuel
Quinn Emanuel Urquhart & Sullivan LLP secured a $310 million earnout deal for former shareholders in biotech company Syntimmune following a seven-day trial in the Delaware Court of Chancery, earning the...To view the full article, register now.
Already a subscriber? Click here to view full article